

Ticker: **SOLV US EQUITY****Solventum Corp (New York: SOLV, Currency: USD)**

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

Website: www.solventum.com
 Number of Employees: --
 Ticker: SOLV US

3M Center, Building 275-6W 2510 Conway Avenue East St Paul, MN 55144 United States
 Phone : 1-651-733-1110
 Fax : --

↑ **66.25** +0.18 (0.27%)
 06/07 0.3

Solventum Corporation ofrece soluciones de atención médica. Desarrolla, fabrica y comercializa soluciones que aprovechan las capacidades de la ciencia de materiales y datos, la investigación clínica y digitales. Opera en el mercado de separación y purificación, información sanitaria, soluciones médicas, componentes de dispositivos médicos y cuidado bucal.


Stock Quote & Chart (Currency: USD)

Last (delayed quote)	66.25	Market Cap (MM)	11,461.4
Open	66.00	Shares Out. (MM)	173.0
Previous Close	66.07	Float %	80.1%
Change	0.00	Shares sold short (MM)	4,388,315.0
Change %	0.00	Dividend Yield %	--
Day High/Day Low	66.7 / 65.4	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	85.9 / 47.2	P / Diluted EPS Before XO	
Volume (MM)	0.73	Beta	--
Avg. Vol - 3 mo (MM)	1.16		

Financial Information (Currency: USD, in mm)

Revenue - LTM	8,253.0	Cash & ST Invest.	762
EBIT - LTM	1,036.0	Total Assets	14,457.0
EBITDA - LTM	1,591.0	Total Debt	8,183.0
Net Income - LTM	478.0	Total Liabilities	11,498.0
Total Enterprise Value	18,882	Total Equity	2,959.0
TEV/ Total Revenue	2.3 x	Cash from Operations - LTM	1,185.0
TEV/ EBITDA	11.8 x	Cash From Investing - LTM	-380.0
		Cash from Financing -LTM	-237.0

FECHA: 29/04/2025

**Company Notes**

2013 Q1
 GAAP Net Income includes, (in millions, pre-tax):
 a loss of \$3.00 from Litigation

2012 Q3
 GAAP Net Income includes, (in millions, pre-tax):
 a loss of \$4.098.00 from Litigation

2011 A1
 GAAP Net Income includes, (in millions, pre-tax):
 a loss of \$7.00 from Litigation

2011 Q4
 GAAP Net Income includes, (in millions, pre-tax):
 a loss of \$1.00 from Litigation

2011 Q2
 GAAP Net Income includes, (in millions, pre-tax):
 A loss of \$6.000 from Litigation

2010 A1
 GAAP Net Income includes, (in millions, pre-tax):
 a gain of \$45.00 from Litigation


2010 Q4
 GAAP Net Income includes, (in millions, pre-tax):
 a gain of \$4.00 from Litigation

Key Board Members

Name	Title	Organization
1 Glenn A Eisenberg	Exec Vp/Treasurer	Fortrea Llc
2	Executive Vice President	Labcorp Holdings Inc
3	Board Member	Solventum Corp
4 Bernard A Harris	President/Founder	Harris Foundation
5	President	Pbi Inc
6	Lead Director	Us Physical Therapy Inc
7	Board Member	Solventum Corp
8	Board Member	Rtx Corp
9	Board Member	Massachusetts Mutual Life Insu
#	Board Member	Houston Exponential Inc
# Karen J May	Board Member	Solventum Corp
#	Board Member	Alcon Inc
#	Board Member	Ace Hardware Corp
#	Board Member	Mbi Financial Inc
# John H Weiland	Board Member	Solventum Corp
# Carrie Smith Cox	Chairman	Solventum Corp
#	Chairman	Cartesian Therapeutics Inc
#	Chairman	Organon & Co
#	Board Member	Texas Instruments Inc
# Amy A McBride-Wendell	Board Member	Solventum Corp
#	Board Member	Baxter Intl Inc
#	Lead Director	Axogen Inc
#	Board Member	Hologic Inc
# Susan Dodson Devore	Board Member	Solventum Corp
#	Board Member	Elevance Health Inc
#	Board Member	Unum Group
#	Trustee	University Of North Carolina A
# Carlos Alban	Board Member	Solventum Corp
#	Board Member	Springworks Therapeutics Inc


Ticker: SOLV US EQUITY		Solventum Corp												
Period Type		Annuals		Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos										
Annuals		FY												
		-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY		
Key Financials														
		Actuals							LTM	Estimates				
For the Fiscal Period Ending		--	--	--	31/12/2021	31/12/2022	31/12/2023	31/12/2024	31/12/2024	31/12/2025	31/12/2026	31/12/2027		
Currency		USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD		
The Western Union Company ofrece servicios de movimiento de dinero y pago mundiales. Se centra en ofrecer a personas y empresas formas rápidas, confiables y seguras de enviar dinero.														
Total Revenue		--	--	--	8,171.0	8,130.0	8,197.0	8,254.0	2,074.0	8,254.0	2,014.9	2,014.9		
Growth Over Prior Year		--	--	--	--	(0.5%)	0.8%	0.7%	--	(0.1%)	(0.1%)	(0.1%)		
Gross Profit		--	--	--	4,923.0	4,695.0	4,693.0	4,593.0	4,593.0	--	--	--		
Margin %		--	--	--	60.2%	57.7%	57.3%	55.6%	221.5%	--	--	--		
EBITDA		--	--	--	2,476.0	2,303.0	2,281.0	1,666.0	1,591.0	418.8	418.8	418.8		
Margin %		--	--	--	30.3%	28.3%	27.8%	20.2%	76.7%	5.1%	20.8%	20.8%		
EBIT		--	--	--	1,879.0	1,693.0	1,692.0	1,036.0	1,036.0	383.6	383.6	383.6		
Margin %		--	--	--	23.0%	20.8%	20.6%	12.6%	50.0%	4.6%	19.0%	19.0%		
Earnings from Cont. Ops.		--	--	--	1,460.0	1,343.0	1,346.0	479.0	478.0	--	--	--		
Margin %		--	--	--	17.9%	16.5%	16.4%	5.8%	23.0%	--	--	--		
Net Income		--	--	--	1,460.0	1,343.0	1,346.0	479.0	478.0	176.3	176.3	176.3		
Margin %		--	--	--	17.9%	16.5%	16.4%	5.8%	23.0%	2.1%	8.8%	8.8%		
Diluted EPS Excl. Extra Items		--	--	--	--	--	--	2.8	2.8	1.2	1.2	1.2		
Growth Over Prior Year		--	--	--	--	--	--	--	--	(41.9%)	(41.9%)	(41.9%)		

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	66.25
Shares Out.	173.00
Market Capitalization (USD)	11,461.44
- Cash & Short Term Investments	762.00
+ Total Debt	8,183.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	18,882.44
Book Value of Common Equity	2,959.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	8,183.00
= Total Capital	11,142.00



Valuation Multiples based on Current Capitalization					
For the Fiscal Period Ending	Actual	LTM	Estimates		
	31/12/2024	31/12/2024	31/12/2024	31/12/2024	31/12/2024
TEV/Total Revenue	2.3x	2.3x	9.3x	9.3x	9.3x
TEV/EBITDA	11.3x	11.8x	10.3x	10.3x	10.3x
TEV/EBIT	18.1x	18.2x	11.2x	11.2x	11.2x
P/Diluted EPS Before Extra	23.9x	24.0x	--	--	--
P/BV	3.9x	3.9x	--	--	--
Price/Tang BV	--	--	--	--	--

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	13.7x	11.9x	11.9x	11.9x
TEV / EBITDA	11.8x	10.3x	10.3x	10.3x
Price / CF	9.7x	15.1x	15.1x	15.1x
Price / Book	3.9x	0.0x	0.0x	0.0x
Dividend Yield	0.0x	0.0x	0.0x	0.0x



Ticker:	SOLV US EQUITY	SOLV US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Solventum Corp

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:											
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	-	-	-	-	-	-	-	8,171.00	8,130.00	8,197.00	8,254.00
Other Revenue	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	-	-	-	-	-	-	-	8,171.00	8,130.00	8,197.00	8,254.00
Cost Of Goods Sold	-	-	-	-	-	-	-	3,248.00	3,435.00	3,504.00	3,661.00
Gross Profit	-	-	-	-	-	-	-	4,923.00	4,695.00	4,693.00	4,593.00
Selling General & Admin Exp.	-	-	-	-	-	-	-	2,278.00	2,235.00	2,243.00	2,782.00
R & D Exp.	-	-	-	-	-	-	-	766.00	767.00	758.00	775.00
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense, Total	-	-	-	-	-	-	-	3,044.00	3,002.00	3,001.00	3,557.00
Operating Income	-	-	-	-	-	-	-	1,879.00	1,693.00	1,692.00	1,036.00
Interest Expense	-	-	-	-	-	-	-	-	-	-	367.00
Interest Income	-	-	-	-	-	-	-	-	-	-	-
Net Interest Exp.	-	-	-	-	-	-	-	-	-	-	367.00
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	-	-	-	-	-	-	-	(3.00)	1.00	25.00	39.00
EBT Excl. Unusual Items	-	-	-	-	-	-	-	1,882.00	1,692.00	1,667.00	630.00
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	25.00
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	(50.00)
EBT Incl. Unusual Items	-	-	-	-	-	-	-	1,882.00	1,692.00	1,667.00	605.00
Income Tax Expense	-	-	-	-	-	-	-	422.00	349.00	321.00	126.00
Earnings from Cont. Ops.	-	-	-	-	-	-	-	1,460.00	1,343.00	1,346.00	479.00
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	1,460.00	1,343.00	1,346.00	479.00
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	-	-	-	-	-	-	-	1,460.00	1,343.00	1,346.00	479.00
Abnormal Losses (Gains)	-	-	-	-	-	-	-	-	-	(56.00)	480.00
Tax Effect on Abnormal Items	-	-	-	-	-	-	-	-	-	11.76	(98.00)
NI to Common Excl. Extra Items	-	-	-	-	-	-	-	1,460.00	1,343.00	1,301.76	871.00
Per Share Items											
Basic EPS	-	-	-	-	-	-	-	-	-	-	2.77
Basic EPS Excl. Extra Items	-	-	-	-	-	-	-	-	-	-	2.77
Weighted Avg. Basic Shares Out.	-	-	-	-	-	-	-	-	-	-	173.20
Diluted EPS	-	-	-	-	-	-	-	-	-	-	2.76
Diluted EPS Excl. Extra Items	-	-	-	-	-	-	-	-	-	-	2.76
Weighted Avg. Diluted Shares Out.	-	-	-	-	-	-	-	-	-	-	173.70
Normalized Basic EPS	-	-	-	-	-	-	-	-	-	-	6.70
Normalized Diluted EPS	-	-	-	-	-	-	-	-	-	-	5.02
Dividends per Share	-	-	-	-	-	-	-	-	-	-	-
Payout Ratio %	-	-	-	-	-	-	-	-	-	-	-
Supplemental Items											
EBITA	-	-	-	-	-	-	-	2,292.00	2,126.00	2,117.00	1,485.00
EBIT	-	-	-	-	-	-	-	1,879.00	1,693.00	1,692.00	1,036.00
As Reported Total Revenue*	-	-	-	-	-	-	-	8,171.00	8,130.00	8,197.00	8,254.00
Effective Tax Rate %	-	-	-	-	-	-	-	22.42	20.63	19.26	20.83
Normalized Net Income	-	-	-	-	-	-	-	1,460.00	1,343.00	1,301.76	871.00
Interest Capitalized	-	-	-	-	-	-	-	-	-	-	-
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	-	-	-	-	-	-	-	38.00	37.00	39.00	112.00
Stock-Based Comp., Total	-	-	-	-	-	-	-	38.00	37.00	39.00	112.00

SOLV US EQUITY	Ascend	▼
Consolidated	Yes	▼

Solventum Corp

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

Ticker:	SOLV US EQUITY	Sort	Ascend	Currency Selection	☒ Reporting	☐ Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting Standard	Mixed		

Solventum Corp

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

[illegible]

Accounting Mixed

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

[illegible]

Accounting Mixed

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

	-15PQ	-12Q	-8PQ	-7PQ	-6PQ	-5PQ	-4PQ	-3PQ	-2PQ	-1PQ	-0PQ
For the Fiscal Period Ending											
Profitability								31/03/2024	30/06/2024	30/09/2024	31/12/2024
Return on Assets											
Return on Capital											
Return on Equity											
Margin Analysis											
Gross Margin								58.1%	54.6%	56.0%	54.0%
SO&A Margin											
EBIT&A Margin											19.3%
EBIT Margin											12.8%
Earnings from Cont. Ops Margin								18.9%	11.7%	12.2%	6.5%
Net Income Margin								11.8%	4.3%	5.9%	1.4%
Normalized Net Income Margin								12.8%	9.4%	10.2%	8.3%
Free Cash Flow Margin								16.9%	14.3%	3.7%	4.4%
Asset Turnover											
Total Asset Turnover											
Fixed Asset Turnover											
Accounts Receivable Turnover											
Inventory Turnover											
Over Time Usability											
Current Ratio								1.8x	1.3x	1.7x	1.7x
Quick Ratio								1.7x	0.7x	0.6x	0.7x
Cash from Ops. To Fund Liab.								0.7x	0.7x	0.7x	
Cap. Flow Sales Pct											
Cap. Flow Inventory Pct											
Cap. Flow Payable Pct											
Cap. Flow Dividends Pct											
Free Term Solvency											
Total Debt/Equity								715.6%	389.7%	744.0%	736.1%
Total Debt/Total Capital								68.1%	72.1%	71.1%	71.4%
LT Debt/Equity								715.6%	389.7%	744.0%	744.0%
LT Debt/Current								68.1%	74.1%	69.1%	70.4%
Total Liabilities/Total Assets								61.7%	67.7%	68.7%	69.6%
EBIT / Interest Pay								6.77x	7.14x	7.57x	1.77x
EBIT&A / Interest Pay								13.15x	3.31x	3.81x	7.67x
EBIT&A (CapEx) / Interest Pay								10.77x	7.80x	7.84x	1.48x
Total Debt/EBIT&A											5.14x
Net Debt/EBIT&A											4.66x
Altman Z Score								0.76	0.67	0.99	1.88
Growth Over Prior Year											
Total Revenue											
Gross Profit											
EBIT&A											
EBIT											
Earnings from Prior Pct											
Net Income											
Normalized Net Income											
Diluted EPS before Extra											
Accounts Receivable											
Inventory											
Net PP&E											
Total Assets											
Tangible Book Value											
Common Equity											
Cash from Ops.											
Capital Expenditures											
Unlevered Free Cash Flow											
Unlevered Free Cash Flow											
Dividend per Share											
FC&B Over Two Years											
Total Revenue											
Gross Profit											
EBIT&A											
EBIT											
Earnings from Cont. Ops.											
Net Income											
Normalized Net Income											
Diluted EPS before Extra											
Accounts Receivable											
Inventory											
Net PP&E											
Total Assets											
Tangible Book Value											
Common Equity											
Cash from Ops.											
Capital Expenditures											
Unlevered Free Cash Flow											
Unlevered Free Cash Flow											
Dividend per Share											

Bloomberg

Company In Depth Fundamentals - Capital Structure Summary

Ticker:	SOLV US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Quarters	Consolidated	Yes	Accounting	Mixed		

Solentum Corp

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

y	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
WACC					
For the Fiscal Period Ending		31/03/2024	30/06/2024	30/09/2024	31/12/2024
	%	%	%	%	%
Equity					
Cost of Equity	--	9.7%	8.3%	4.8%	6.8%
Weight of Equity	--	59.1%	52.4%	59.8%	58.2%
+ Debt					
Cost of Debt	--	4.5%	6.0%	4.1%	5.3%
Weight of Debt	--	40.9%	47.6%	40.2%	41.8%
+ Preferred Equity					
Cost of Pref Equity	--				
Weight of Pref Equity	--	0.0%	0.0%	0.0%	0.0%
WACC	--	7.5%	7.2%	4.5%	6.2%

Capital Structure										
For the Fiscal Period Ending		31/03/2024		30/06/2024		30/09/2024		31/12/2024		
Currency		USD		USD		USD		USD		
	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total
Net Market Cap	--	--	0.0	0.0%	0.0	0.0%	300.0	1.5%	287.0	1.5%
LT Borrowings	--	--	8,303.0	40.9%	8,306.0	47.6%	7,809.0	38.7%	7,896.0	40.3%
Pref Equity	--	--	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%
Total Capital	0.0	0.0%	20,314.9	100.0%	17,438.9	100.0%	20,170.6	100.0%	19,597.2	100.0%

Debt Summary Data											
For the Fiscal Period Ending		31/03/2024		30/06/2024		30/09/2024		31/12/2024			
Currency	USD	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total		
Total Commercial Paper	--	--	--	2,000.0	24.1%	2,000.0	24.1%	2,000.0	24.7%	2,000.0	24.4%
Total Revolving Credit	--	--	--	--	--	--	--	--	--	0.0	0.0%
Total Capital Leases	--	--	--	6,306.0	75.9%	6,306.0	75.9%	6,183.0	75.3%	6,183.0	75.6%
General/Other Borrowings	--	--	--	8,303.0	100.0%	8,306.0	100.0%	8,109.0	100.0%	8,183.0	100.0%
Total Principal Due	--	--	--	8,303.0		8,306.0		8,109.0		8,183.0	
Total Debt Outstanding	--	--	--	8,303.0		8,306.0		8,109.0		8,183.0	

Additional Totals										
Total Cash & ST Investments	--	--	996.0	12.0%	897.0	10.8%	772.0	9.5%	762.0	9.3%
Net Debt	--	--	7,307.0	88.0%	7,409.0	89.2%	7,337.0	90.5%	7,421.0	90.7%
Total Short-Term Borrowings	--	--	0.0	0.0%	0.0	0.0%	300.0	3.7%	287.0	3.5%
Curr. Port. of LT Debt/Cap. Leases	--	--	0.0	0.0%	0.0	0.0%	300.0	3.7%	287.0	3.5%
Lone-Term Debt (Incl. Cap. Leases)	--	--	8,303.0	100.0%	8,306.0	100.0%	7,809.0	96.3%	7,896.0	96.5%
Total Secured Debt	--	--	--	--	--	--	--	--	--	--
Fixed Rate Debt	--	--	--	--	--	--	--	--	--	--
Variable Rate Debt	--	--	--	--	--	--	--	--	--	--

Credit Ratios						
Net Debt/EBITDA	--	--	--	--		4.7x
Total Debt/EBITDA	--	--	--	--		5.1x
Operating Income/Total Debt	--	0.0x	0.0x	0.0x		0.0x
LTM FCF/Total Debt	--	--	--	--		0.1x
LTM FCF/Total Debt	--	--	--	--		0.1x
FRIT/Interest Expense	--	9.8x	2.1x	2.6x		1.3x
FRIT/Total Interest Expense	--	9.8x	2.1x	2.6x		1.3x
Degree of Financial Leverage	--	1.1x	1.9x	1.6x		4.7x
EBITDA-CAPEX/Interest Expense	--	10.7x	2.8x	2.9x		1.5x
EBITDA/Total Interest Expense	--	13.3x	3.3x	3.8x		2.7x

Debt Schedule									
Debt Schedule in Yr 1	--	--	--	--	--	300.0	3.7%	200.0	2.5%
Debt Schedule in Yr 2	--	--	--	--	--	979.0	12.1%	979.0	12.2%
Debt Schedule in Yr 3	--	--	--	--	--	994.0	12.3%	995.0	12.4%
Debt Schedule in Yr 4	--	--	--	--	--	1,487.0	18.3%	1,487.0	18.6%
Debt Schedule in Yr 5	--	--	--	--	--	2,626.0	32.4%	2,626.0	32.8%
Debt Schedule - Years 2 - 3	--	--	--	--	--	1,973.0	24.3%	1,974.0	24.6%
Debt Schedule - Years 4 - 5	--	--	--	--	--	4,113.0	50.7%	4,113.0	51.3%
Debt Schedule - Years 2 - 5	--	--	--	--	--	6,086.0	75.1%	6,087.0	76.0%
Debt Schedule Beyond Yr 5	--	--	--	--	--	1,723.0	21.2%	1,723.0	21.5%
Debt Schedule - Total Debt	8,303.0	100.0%	8,306.0	100.0%	8,109.0	100.0%	8,010.0	100.0%	

Capital Lease Schedule										
Capital Leases - Year 1	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 2	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 3	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 4	--	--	--	--	--	--	--	--	--	--
Capital Leases - Year 5	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 3	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 4 - 5	--	--	--	--	--	--	--	--	--	--
Capital Leases - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Capital Leases Beyond Year 5	--	--	--	--	--	--	--	--	--	--
Total Future Value of Capital Leases	--	--	--	--	--	--	--	--	--	0.0
Present Value of ST Capital Leases	--	--	--	--	--	--	--	--	--	0.0
Present Value of LT Capital Leases	--	--	--	--	--	--	--	--	--	0.0

Depreciation Expense (Rental Expense) Schedule									
Rental Expense - Year 1	--	--	--	--	--	--	89.0	50.6%	
Rental Expense - Year 2	--	--	--	--	--	--	44.0	25.0%	
Rental Expense - Year 3	--	--	--	--	--	--	22.0	12.5%	
Rental Expense - Year 4	--	--	--	--	--	--	10.0	5.7%	
Rental Expense - Year 5	--	--	--	--	--	--	4.0	2.3%	
Rental Expense - Years 2 - 3	--	--	--	--	--	--	66.0	37.5%	
Rental Expense - Years 4 - 5	--	--	--	--	--	--	14.0	8.0%	
Rental Expense - Years 2 - 5	--	--	--	--	--	--	80.0	45.5%	
Rental Expense Beyond Year 5	--	--	--	--	--	--	7.0	4.0%	
Total Sublease Income	--	--	--	--	--	--			
Future Min Oper Lease Obligations	--	--	--	--	--	--	176.0	100.0%	

Contractual Obligation Schedule										
Contractual Obligations - Year 1	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 2-3	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 4-5	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Beyond Year 5	--	--	--	--	--	--	--	--	--	--
Total Contractual Obligations	--	--	--	--	--	--	--	--	--	--

Purchase Obligations	--	--	--	--	--	--	--	--
----------------------	----	----	----	----	----	----	----	----

Interest Rate Data					
W/Ave. Interest Rate - Lone-term Debt	--	--	--	--	--

Period Type **Annuals** 

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

[illegible]

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Ticker:	SOLV US EQUITY	
Period Type	Annuals	▼

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

[illegible]

Period Type	Annuals	
-------------	---------	---

Sector: Salud Industry: Equipo y servicios médicos Sub-Industry: Suministros médicos

[illegible]